Loading...
Loading...
BLU| Name | Value |
|---|---|
| Revenues | 1,522.2M |
| Cost of Revenue | 1,446.4M |
| Gross Profit | 75.8M |
| Operating Expense | 94.5M |
| Operating I/L | -39.5M |
| Other Income/Expense | 18.7M |
| Interest Income | 2.1M |
| Pretax | -20.8M |
| Income Tax Expense | 1.4M |
| Net Income/Loss | -22.2M |
BELLUS Health Inc. is a clinical stage biopharmaceutical company specializing in the development of therapeutics for refractory chronic cough (RCC) and other cough hypersensitivity indications. Their lead product candidate, BLU-5937, is an antagonist of the P2X3 receptor currently in Phase II clinical trial for the treatment of RCC and chronic pruritus.
